These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 31276586)

  • 1. Establishment of patient-derived orthotopic xenograft model of 1q+ posterior fossa group A ependymoma.
    Pierce AM; Witt DA; Donson AM; Gilani A; Sanford B; Sill M; Van Court B; Oweida A; Prince EW; Steiner J; Danis E; Dorris K; Hankinson T; Handler MH; Jones KL; Karam SD; Serkova NJ; Vibhakar R; Foreman NK; Griesinger AM
    Neuro Oncol; 2019 Dec; 21(12):1540-1551. PubMed ID: 31276586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma.
    Griesinger AM; Calzadilla AJ; Grimaldo E; Donson AM; Amani V; Pierce AM; Steiner J; Kargar S; Serkova NJ; Bertrand KC; Wright KD; Vibhakar R; Hankinson T; Handler M; Lindsay HB; Foreman NK; Dorris K
    Clin Cancer Res; 2024 Apr; 30(8):1544-1554. PubMed ID: 38334950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of 2 Novel Ependymoma Cell Lines With Chromosome 1q Gain Derived From Posterior Fossa Tumors of Childhood.
    Amani V; Donson AM; Lummus SC; Prince EW; Griesinger AM; Witt DA; Hankinson TC; Handler MH; Dorris K; Vibhakar R; Foreman NK; Hoffman LM
    J Neuropathol Exp Neurol; 2017 Jul; 76(7):595-604. PubMed ID: 28863455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
    Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
    Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of chromosome 1q gain in intracranial ependymomas.
    Rajeshwari M; Sharma MC; Kakkar A; Nambirajan A; Suri V; Sarkar C; Singh M; Saran RK; Gupta RK
    J Neurooncol; 2016 Apr; 127(2):271-8. PubMed ID: 26725097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.
    Gojo J; Lötsch D; Spiegl-Kreinecker S; Pajtler KW; Neumayer K; Korbel P; Araki A; Brandstetter A; Mohr T; Hovestadt V; Chavez L; Kirchhofer D; Ricken G; Stefanits H; Korshunov A; Pfister SM; Dieckmann K; Azizi AA; Czech T; Filipits M; Kool M; Peyrl A; Slavc I; Berger W; Haberler C
    Neuro Oncol; 2017 Sep; 19(9):1183-1194. PubMed ID: 28371821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity within the PF-EPN-B ependymoma subgroup.
    Cavalli FMG; Hübner JM; Sharma T; Luu B; Sill M; Zapotocky M; Mack SC; Witt H; Lin T; Shih DJH; Ho B; Santi M; Emery L; Hukin J; Dunham C; McLendon RE; Lipp ES; Gururangan S; Grossbach A; French P; Kros JM; van Veelen MC; Rao AAN; Giannini C; Leary S; Jung S; Faria CC; Mora J; Schüller U; Alonso MM; Chan JA; Klekner A; Chambless LB; Hwang EI; Massimino M; Eberhart CG; Karajannis MA; Lu B; Liau LM; Zollo M; Ferrucci V; Carlotti C; Tirapelli DPC; Tabori U; Bouffet E; Ryzhova M; Ellison DW; Merchant TE; Gilbert MR; Armstrong TS; Korshunov A; Pfister SM; Taylor MD; Aldape K; Pajtler KW; Kool M; Ramaswamy V
    Acta Neuropathol; 2018 Aug; 136(2):227-237. PubMed ID: 30019219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: A multicenter study.
    Donson AM; Bertrand KC; Riemondy KA; Gao D; Zhuang Y; Sanford B; Norris GA; Chapman RJ; Fu R; Willard N; Griesinger AM; Ribeiro de Sousa G; Amani V; Grimaldo E; Hankinson TC; Booker F; Sill M; Grundy RG; Pajtler KW; Ellison DW; Foreman NK; Ritzmann TA
    Neuro Oncol; 2023 Oct; 25(10):1854-1867. PubMed ID: 37246777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas.
    Godfraind C; Kaczmarska JM; Kocak M; Dalton J; Wright KD; Sanford RA; Boop FA; Gajjar A; Merchant TE; Ellison DW
    Acta Neuropathol; 2012 Aug; 124(2):247-57. PubMed ID: 22526017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features - a retrospective analysis of the HIT ependymoma trial cohort.
    Jünger ST; Mynarek M; Wohlers I; Dörner E; Mühlen AZ; Velez-Char N; von Hoff K; Rutkowski S; Warmuth-Metz M; Kortmann RD; Timmermann B; Rahmann S; Klein-Hitpass L; von Bueren AO; Pietsch T
    Acta Neuropathol Commun; 2019 Nov; 7(1):181. PubMed ID: 31727173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo.
    Yu L; Baxter PA; Voicu H; Gurusiddappa S; Zhao Y; Adesina A; Man TK; Shu Q; Zhang YJ; Zhao XM; Su JM; Perlaky L; Dauser R; Chintagumpala M; Lau CC; Blaney SM; Rao PH; Leung HC; Li XN
    Neuro Oncol; 2010 Jun; 12(6):580-94. PubMed ID: 20511191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective analysis of recurrent pediatric ependymoma reveals extremely poor survival and ineffectiveness of current treatments across central nervous system locations and molecular subgroups.
    Ritzmann TA; Rogers HA; Paine SML; Storer LCD; Jacques TS; Chapman RJ; Ellison D; Donson AM; Foreman NK; Grundy RG
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28426. PubMed ID: 32614133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas.
    Pajtler KW; Wen J; Sill M; Lin T; Orisme W; Tang B; Hübner JM; Ramaswamy V; Jia S; Dalton JD; Haupfear K; Rogers HA; Punchihewa C; Lee R; Easton J; Wu G; Ritzmann TA; Chapman R; Chavez L; Boop FA; Klimo P; Sabin ND; Ogg R; Mack SC; Freibaum BD; Kim HJ; Witt H; Jones DTW; Vo B; Gajjar A; Pounds S; Onar-Thomas A; Roussel MF; Zhang J; Taylor JP; Merchant TE; Grundy R; Tatevossian RG; Taylor MD; Pfister SM; Korshunov A; Kool M; Ellison DW
    Acta Neuropathol; 2018 Aug; 136(2):211-226. PubMed ID: 29909548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma.
    Merchant TE; Bendel AE; Sabin ND; Burger PC; Shaw DW; Chang E; Wu S; Zhou T; Eisenstat DD; Foreman NK; Fuller CE; Anderson ET; Hukin J; Lau CC; Pollack IF; Laningham FH; Lustig RH; Armstrong FD; Handler MH; Williams-Hughes C; Kessel S; Kocak M; Ellison DW; Ramaswamy V
    J Clin Oncol; 2019 Apr; 37(12):974-983. PubMed ID: 30811284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated CXorf67 Expression in PFA Ependymomas Suppresses DNA Repair and Sensitizes to PARP Inhibitors.
    Han J; Yu M; Bai Y; Yu J; Jin F; Li C; Zeng R; Peng J; Li A; Song X; Li H; Wu D; Li L
    Cancer Cell; 2020 Dec; 38(6):844-856.e7. PubMed ID: 33186520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children's Cancer Leukaemia Group (CCLG), Societe Francaise d'Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP).
    Kilday JP; Mitra B; Domerg C; Ward J; Andreiuolo F; Osteso-Ibanez T; Mauguen A; Varlet P; Le Deley MC; Lowe J; Ellison DW; Gilbertson RJ; Coyle B; Grill J; Grundy RG
    Clin Cancer Res; 2012 Apr; 18(7):2001-11. PubMed ID: 22338015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of global 5-hydroxymethylcytosine in pediatric posterior fossa ependymoma.
    Wu T; Zhang ZW; Li S; Wang B; Yang Z; Li P; Zhang J; Tong WM; Li C; Zhao F; Niu Y; Liu P
    Clin Epigenetics; 2020 Jan; 12(1):19. PubMed ID: 31992357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma.
    Thomas C; Thierfelder F; Träger M; Soschinski P; Müther M; Edelmann D; Förster A; Geiler C; Kim HY; Filipski K; Harter PN; Schittenhelm J; Eckert F; Ntoulias G; May SA; Stummer W; Onken J; Vajkoczy P; Schüller U; Heppner FL; Capper D; Koch A; Kaul D; Paulus W; Hasselblatt M; Schweizer L
    Acta Neuropathol; 2021 Jun; 141(6):959-970. PubMed ID: 33755803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and characterization of human ependymoma xenograft HxBr5.
    Horowitz ME; Parham DM; Douglass EC; Kun LE; Houghton JA; Houghton PJ
    Cancer Res; 1987 Jan; 47(2):499-504. PubMed ID: 3791238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent pediatric infratentorial ependymomas: a systematic review and meta-analysis on outcomes and molecular classification.
    Montgomery EY; Thirunavu V; Pagadala M; Shlobin NA; Plant-Fox AS; Lam S; DeCuypere M
    J Neurosurg Pediatr; 2023 Feb; 31(2):132-142. PubMed ID: 36433871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.